Heron Therapeutics Inc vs InMode Ltd — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while InMode Ltd trades at $15.16 (market cap $873.13M). The key difference: InMode Ltd is far larger — about 13.8× Heron Therapeutics Inc's market cap, and InMode Ltd is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | INMD | |
|---|---|---|
Market Cap | $63.41M | $873.13M |
Sector | Health | Technology |
52-Week High | $1.49 | $16.62 |
52-Week Low | $0.32 | $12.76 |
Enterprise Value | $161.31M | $376.47M |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
InMode (INMD) trades at $15.31, up 1.26% with a bullish technical outlook. The stock shows strong profitability with 76.52% gross margins and 20.69% net income margin, though 2026 earnings guidance suggests margin compression. Recent developments include an unsolicited acquisition offer from Steel Partners at $16.75 per share and ongoing shareholder activism. Technical indicators show bullish moving averages with neutral oscillators, while analyst consensus is divided between Buy and Hold ratings.
The investment case balances attractive valuation metrics (P/E 12.55, EV/EBITDA 5.39) against execution risks and shareholder disputes. Near-term catalysts include the Q3 2026 earnings report and potential acquisition developments. Key risks involve competitive pressures in medical aesthetics and ongoing securities investigations that could impact investor confidence.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →